Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / DARE - FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia Seeks Additional Funding | Benzinga

DARE - FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia Seeks Additional Funding | Benzinga

Dare Bioscience Inc.

Daré Bioscience Inc (NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of VVA associated with menopause. 

With the IND clearance from the FDA, Daré can begin planning for an anticipated Phase ...

Full story available on Benzinga.com
Stock Information
Company Name: Dare Bioscience Inc.
Stock Symbol: DARE
Market: NASDAQ
Website: darebioscience.com
Menu
DARE DARE Quote DARE Short DARE News DARE Articles DARE Message Board
Get DARE Alerts

News, Short Squeeze, Breakout and More Instantly...